Erlie Jiang

3.2k total citations · 1 hit paper
202 papers, 1.5k citations indexed

About

Erlie Jiang is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Erlie Jiang has authored 202 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Hematology, 49 papers in Immunology and 44 papers in Oncology. Recurrent topics in Erlie Jiang's work include Hematopoietic Stem Cell Transplantation (98 papers), Acute Myeloid Leukemia Research (62 papers) and Acute Lymphoblastic Leukemia research (30 papers). Erlie Jiang is often cited by papers focused on Hematopoietic Stem Cell Transplantation (98 papers), Acute Myeloid Leukemia Research (62 papers) and Acute Lymphoblastic Leukemia research (30 papers). Erlie Jiang collaborates with scholars based in China, United States and United Kingdom. Erlie Jiang's co-authors include Sizhou Feng, Mingzhe Han, Donglin Yang, Jialin Wei, Mingzhe Han, Weihua Zhai, Qiaoling Ma, Yi He, Mingfeng Zhao and Jie Cao and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Erlie Jiang

165 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

2021 150 citations Mingzhe Han, Erlie Jiang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erlie Jiang China	20	633	343	307	305	280	202	1.5k
Sizhou Feng China	18	377 0.6×	212 0.6×	296 1.0×	186 0.6×	230 0.8×	160	1.1k
A Iacone Italy	20	585 0.9×	312 0.9×	451 1.5×	193 0.6×	381 1.4×	82	1.5k
Marta Stanzani Italy	20	418 0.7×	249 0.7×	156 0.5×	485 1.6×	359 1.3×	58	1.5k
Masahiro Onozawa Japan	21	365 0.6×	398 1.2×	292 1.0×	351 1.2×	211 0.8×	109	1.3k
Rana Domiati‐Saad United States	20	263 0.4×	208 0.6×	227 0.7×	263 0.9×	584 2.1×	27	1.6k
Yaseelan Palarasah Denmark	23	231 0.4×	294 0.9×	72 0.2×	175 0.6×	678 2.4×	79	1.4k
Anne‐Sophie Moreau United States	18	309 0.5×	317 0.9×	248 0.8×	220 0.7×	256 0.9×	69	1.2k
Susan L. Heatley Australia	18	507 0.8×	371 1.1×	165 0.5×	312 1.0×	752 2.7×	51	1.7k
L. Uharek Germany	22	796 1.3×	223 0.7×	438 1.4×	302 1.0×	795 2.8×	57	1.6k
Christian Koenecke Germany	29	629 1.0×	395 1.2×	718 2.3×	301 1.0×	1.2k 4.4×	108	2.5k

Countries citing papers authored by Erlie Jiang

Since Specialization

Citations

This map shows the geographic impact of Erlie Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erlie Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erlie Jiang more than expected).

Fields of papers citing papers by Erlie Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erlie Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erlie Jiang. The network helps show where Erlie Jiang may publish in the future.

Co-authorship network of co-authors of Erlie Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Erlie Jiang. A scholar is included among the top collaborators of Erlie Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erlie Jiang. Erlie Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Erlie, Yuewen Fu, Xiaojun Xu, et al.. (2025). Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study. Military Medical Research. 12(1). 63–63.

Liang, Chen, Donglin Yang, Aiming Pang, et al.. (2024). Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2127–2127.

Sun, Huimin, Xueying Zhao, Aiming Pang, et al.. (2024). Monocytes as an early risk factor for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Frontiers in Immunology. 15. 1433091–1433091. 1 indexed citations

Jiang, Erlie, Kun Qian, Lu Wang, et al.. (2024). Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial. BMC Medicine. 22(1). 555–555. 6 indexed citations

Lin, Qingsong, Chunhui Xu, Jinrong Sun, et al.. (2024). [Clinical characteristics and prognostic analysis of carbapenem-resistant Enterobacteriaceae bloodstream infections in patients with hematologic diseases].. PubMed. 45(11). 1022–1027.

Wang, Jiali, Xinhui Zheng, Qi Sun, et al.. (2024). Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation. 59(12). 1654–1666. 2 indexed citations

Liu, Huan, Zihan Zhao, Shiyue Zhang, et al.. (2024). Proteinase 3 depletion attenuates leukemia by promoting myeloid differentiation. Cell Death and Differentiation. 31(6). 697–710. 7 indexed citations

Wang, Feng, Yunxuan Li, Zhao-na Yang, et al.. (2024). Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Nature Communications. 15(1). 203–203. 8 indexed citations

Wang, Yan, Jiali Sun, Xin Chen, et al.. (2024). Impact of platelet transfusion refractoriness in the first 30 days post-hematopoietic stem cell transplantation on outcomes of patients with myelodysplastic syndrome. Frontiers in Immunology. 15. 1437176–1437176.

10.

Mo, Xiao‐Dong, He Huang, Feng Chen, et al.. (2024). A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment. Blood. 144(Supplement 1). 99–99. 1 indexed citations

11.

Yao, Yuanyuan, et al.. (2023). Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature. Frontiers in Immunology. 14. 1287456–1287456. 1 indexed citations

12.

He, Yi, Donglin Yang, Qiaoling Ma, et al.. (2023). Inotuzumab Ozogamicin in Lymphoid B Cell Malignancy：a Single Center Analysis in the Real World. Blood. 142(Supplement 1). 5900–5900.

13.

Jiang, Erlie, et al.. (2023). Hematopoietic progenitor cell count as a potential quantitative marker in apheresis products during allogeneic stem cell transplantation. Transfusion. 64(2). 348–356. 1 indexed citations

14.

Shi, Yuanyuan, Guixin Zhang, Yi He, et al.. (2023). Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia. Frontiers in Pharmacology. 14. 1014306–1014306. 1 indexed citations

15.

He, Yi, Donglin Yang, Qiaoling Ma, et al.. (2023). Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease. British Journal of Haematology. 202(2). 369–378. 3 indexed citations

16.

Labopin, Myriam, Thomas Pabst, Xi Zhang, et al.. (2023). Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT. Bone Marrow Transplantation. 58(12). 1322–1330. 4 indexed citations

17.

Liu, Li, Xiaolei Pei, Yi He, et al.. (2023). Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients. SHILAP Revista de lepidopterología. 5(2). 106–110.

18.

Chen, X, Weihua Zhai, Aiming Pang, et al.. (2022). [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].. PubMed. 43(7). 542–549. 3 indexed citations

19.

Huang, Jie, Erlie Jiang, Donglin Yang, et al.. (2020). <p>Metagenomic Next-Generation Sequencing versus Traditional Pathogen Detection in the Diagnosis of Peripheral Pulmonary Infectious Lesions</p>. Infection and Drug Resistance. Volume 13. 567–576. 122 indexed citations

20.

Liu, Xin, Erlie Jiang, Yong Huang, et al.. (2017). Which Patients with Ph+ Acute Lymphoblastic Leukemia Should Undergo Autologous Hematopoietic Stem Cell Transplantation in TKI Era?. Blood. 130. 3286–3286. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact